Effect of renal impairment on the pharmacokinetics of grepafloxacin

Clinical Pharmacokinetics

Volumn 33, Issue SUPPL. 1, 1997, Pages 32-38

  Rodvold, Keith A ^a   Everett, Julie A ^b   Pryka, Randy D ^c   Kraus, Donna M ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b PURDUE UNIVERSITY   (United States)

^c UNIVERSITY OF TOLEDO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GREPAFLOXACIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG EXCRETION; DRUG URINE LEVEL; FEMALE; HEADACHE; HUMAN; KIDNEY CLEARANCE; KIDNEY DISEASE; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TASTE DISORDER; URINARY EXCRETION;

EID: 0031468793     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199700331-00007     Document Type: Article

References (89)

1. Spears RL, Koch R. The use of vancomycin in pediatrics. Antibiotics Ann 1959-1960: 798-803
2. Schaad UB, McCracken GH, Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 1980; 96: 119-26
3. Kaplan EL. Vancomycin in infants and children: a review of pharmacology and indications for therapy and prophylaxis. J Antimicrob Chemother 1984; 14 Suppl. D: 59-66
4. de Louvois J, Harvey D. Antibiotic therapy of the newborn. Clin Perinatol 1988; 15: 365-89
5. Hall SL. Coagulase-negative staphylococcal infections in neonates. Pediatr Infect Dis J 1991; 10: 57-67
6. Patrick CC. Coagulase-negative staphylococci: pathogens with increasing clinical significance. J Pediatr 1990; 116: 497-507
7. Battisti O, Mitchison R, Davies PA. Changing blood culture isolates in a referral neonatal intensive care unit. Arch Dis Child 1981; 56: 775-8
8. Hoogkamp-Korstanje KJ, Cats B, Senders RC, et al. Analysis of bacterial infections in a neonatal intensive care unit. J Hosp Infect 1982; 3: 275-84
9. Hack M, Horbar JD, Malloy MH, et al. Very low birth weight outcomes of the national institute of child health and human development neonatal network. Pediatrics 1991; 87: 587-97
10. Becerra JE, Fry YW, Rowley DL. Morbidity estimates of conditions originating in the perinatal period: United States, 1986 through 1987. Pediatrics 1991; 88: 553-9
11. Edwards MS, Baker CJ. Median sternotomy wound infections in children. Pediatr Infect Dis J 1983; 2: 105-9
12. Scherer LR, West KW, Weber TR, et al. Staphylococcus epidermidis sepsis in pediatric patients: clinical and therapeutic considerations. J Pediatr Surg 1984; 19: 358-61
13. Siegel JD, McCracken GH. Sepsis neonatorum. N Engl J Med 1981; 304: 642-7
14. Friedman LE, Brown AE, Miller DR, et al. Staphylococcus epidermidis septicemia in children with leukemia and lymphoma. Am J Dis Child 1984; 138: 715-9
15. Pryka RD, Rodvold KA, Erdman SM. An updated comparison of drug dosing methods: Part IV: vancomycin. Clin Pharmacokinet 1991; 20: 463-76
16. Leader WG, Chandler MHH, Castiglia M. Pharmacokinetic optimisation of vancomycin therapy. Clin Pharmacokinet 1995; 28: 327-42
17. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994; 18: 533-43
18. Moellering RC. Monitoring serum vancomycin levels: climbing the mountain because it is there? Clin Infect Dis 1994; 18: 544-6
19. Pryka RD. Vancomycin serum concentration monitoring: a continued debate. Ann Pharmacother 1994; 28: 1397-9
20. Saunders NJ. Vancomycin administration and monitoring reappraisal. J Antimicrob Chemother 1995; 36: 279-82
21. Wandstrat TL, Phelps SJ. Vancomycin dosing in neonatal patients: the controversy continues. Neonatal Netw 1994; 13: 33-9
22. Morse GD, Nairn DK, Bertino JS, et al. Overestimation of vancomycin concentrations utilizing fluorescence polarization immunoassay in patients on peritoneal dialysis. Ther Drug Monit 1987; 9: 212-5
23. Anne L, Hu M, Chan K, et al. Potential problem with fluorescence polarization immunoassay cross-reactivity to vancomycin degradation product CDP-1: its detection in sera of renally impaired patients. Ther Drug Monit 1989; 11: 585-91
24. 12 internal standard: comparison of high-performance liquid chromatography, EMIT, and fluorescence polarization immunoassay. Ther Drug Monit 1990; 12: 562-9
25. White LO, Edwards R, Holt HA, et al. The in-vitro degradation at 37°C of vancomycin in serum, CAPD fluid and phosphate-buffered saline. J Antimicrob Chemother 1988; 22: 739-45
26. Harris CM, Kopecka H, Harris TM. Vancomycin: structure and transformation to CDP-1. J Am Chem Soc 1983; 105: 6915-22
27. Paap CM, Sharpe GL. Overestimation of serum vancomycin concentrations using a fluorescence polarization immunoassay (TDx) in preterm neonates. Dev Pharmacol Ther 1993; 20: 174-9
28. Alpert G, Campos JM, Harris MC, et al. Vancomycin dosage in pediatrics reconsidered. Am J Dis Child 1984; 138: 20-2
29. Bailie GR, Ackerman BH, Fischer J, et al. Increased vancomycin dosage requirements in young burn patients. J Burn Care Rehabil 1984; 5: 376-8
30. Gross JR, Kaplan SL, Kramer WG, et al. Vancomycin pharmacokinetics in premature infants. Pediatr Pharmacol 1985; 5: 17-22
31. Amaker RD, DiPiro JT. Bhatia J. Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob Agents Chemother 1996; 40: 1139-42
32. Armstrong DK, Hidalgo HA, Eldadah M. Vancomycin and tobramycin clearance in an infant during continous hemofiltration. Ann Phaimacother 1993; 27: 224-7
33. Asbury WH, Darsey EH, Rose WB, et al. Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation. Ann Pharmacother 1993; 27: 490-6
34. Chang D, Liem L, Malogolowkin M. A prospective study of Vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients. Pediatr Infect Dis J 1994; 13; 969-74
35. Chang D. Influence of malignancy on the pharmacokinetics of Vancomycin in infants and children. Pediatr Infect Dis J 1995; 14; 667-73
36. Gabriel MH, Kildoo CW, Gennrich JL, et al. Prospective evaluation of a Vancomycin dosaae guidelines for neonates. Clin Pharm 1991; 10: 129-32
37. Hatzopoulos FK, Stile-Calligaro IL, Rodvold KA, et al. Pharmacokinetics of intravenous Vancomycin in pediatric cardiopulmonary bypass surgery. Pediatr Infect Dis J 1993; 12: 300-4
38. Hoie EB, Swigart SA, Leuschen MP, et al. Vancomycin pharmacokinetics in infants undergoing extracorporeal membrane oxygenation. Clin Pharm 1990; 9: 711-5
39. Jarrett RV, Marinkovich GA, Gayle EL, et al. Individualized pharmacokinetic profiles to compute vancomycin dosage and dosing interval in preterm infants. Pediatr Infect Dis J 1991; 12: 156-7
40. Kildoo CW, Lin ML, Gabriel MH, et al. Vancomycin pharmacokinetics in infants: relationship to postconceptional age and serum creatinine. Dev Pharmacol Ther 1990; 14: 77-83
41. Koren G, James A. Vancomycin dosing in preterm infants: prospective verification of new dosing recommendation. J Pediatr 1987; 110: 797-8
42. Leonard MB, Keren G, Stevenson DK, et al. Vancomycin pharmacokinetics in very low birth weight neonates. Pediatr Infect Dis J 1989; 8: 282-6
43. Lisby-Sutch SM, Nahata MC. Dosage guidelines for the use of Vancomycin based on its pharmacokinetics in infants. Eur J Clin Pharmacol 1988; 35: 637-42
44. McDougal A, Ling EW, Levine M. Vancomycin pharmacokinetics and dosing in premature neonates. Ther Drug Monit 1995; 17: 319-26
45. Moller JC, Nachtrodt G, Tegtmeyer FK, et al. Prophylactic low-dose vancomycin treatment in very-low-birth-weight infants. Dev Pharmacol Ther 1992; 19: 178-82
46. '46. Reed MD, Kliegman RM, Weiner JS, et al. The clinical pharmacology of vancomycin in seriously ill preterm infants. Pediatr Res 1987; 22: 360-3
47. Rodvold KA, Gentry CA, Plank G, et al. Bayesian forecasting of serum vancomycin concentrations in neonates and infants. Ther Drug Monit 1995; 17: 239-46
48. Schaible DH, Rocci ML, Alpert GA, et al. Vancomycin pharmacokinetics in infants: relationships to indices of maturation. Pediatr Infect Dis J 1986; 5: 304-8
49. Seay RE, Brundage RC, Jensen PD, et al. Population pharmacokinetics of vancomycin in neonates. Clin Pharmacol Ther 1994; 56: 169-75
50. Naqvi SH, Keenan WJ, Reichley RM, et al. Vancomycin pharmacokinetics in small, seriously ill infants. Am J Dis Child 1986; 140: 107-10
51. James A, Koren G, Milliken J, et al. Vancomycin pharmacokinetics and dose recommendations for preterm infants. Antimicrob Agents Chemother 1987; 31: 52-4
52. Riley HD, Ryan NJ. Treatment of severe staphylococcal infection in infancy and childhood with vancomycin. Antibiotic Ann 1959-1960: 908-16
53. Rodvold KA, Erdman SM, Pryka RD. Vancomycin. In: Schumacher GE, editor. Therapeutic drug monitoring. Norwalk: Appleton & Lange, 1996: 587-664
54. Schaad UB, Nelson JD, McCracken GH. Pharmacology and efficacy of vancomycin for staphylococcal infections in children. Rev Infect Dis 1981; 3 Suppl.: 282-8.
55. Levy M, Koren G, Dupuis L, et al. Vancomycin-induced red man syndrome. Pediatrics 1990; 86: 572-80
56. Odio C, Mohs E, Sklar FH, et al. Adverse reactions to vancomycin used as prophylaxis for CSF shunt procedures. Am J Dis Child 1984; 138: 17-9
57. Boussemart T, Cardona J, Bertheir M, et al. Cardiac arrest associated with vancomycin in a neonate [letter]. Arch Dis Child Fetal Neonatal 1995; 73: 123
58. Best CJ, Ewart M, Sumner E. Perioperative complications following the use of vancomycin in children: a report of two cases. Br J Anaesth 1989; 62: 576-7
59. Mayhew JF, Deutsch S. Cardiac arrest following administration of vancomycin. Can Anaesth Soc J 1985; 32: 65-6
60. Bergeron L, Boucher FD. Possible red-man syndrome associated with systemic absorption of oral vancomycin in a child with normal renal function. Ann Pharmacother 1994; 28: 581-4
61. Burkhart KK, Metcalf S, Shurnas E, et al. Exchange transfusion and multidose activated charcoal following vancomycin over-dose. Clin Toxicol 1992; 30: 285-94
62. Linder N, Edwards R, McClead R, et al. Safety of vancomycin with or without gentamicin in neonates. Neonatal Netw 1993; 12: 27-30
63. Odio C, McCracken GH, Nelson JD. Nephrotoxicity associated with vancomycin-aminoglycoside therapy in four children. J Pediatr 1984; 105: 491-3
64. Dean RP, Wagner DJ, Tolpin MD. Vancomycin/aminoglycoside nephrotoxicity [letter]. J Pediatr 1985; 106: 861-2
65. Tissing WJE, Umans-Eckenhausen MAW, van den Anker JN. Vancomycin intoxication in a preterm neonate [letter]. Eur J Pediatr 1993; 152: 700
66. Goren MP, Baker DK, Shenep JL. Vancomycin does not enhance amikacin-induced tubular nephrotoxicity in children. Pediatr Infect Dis J 1989; 8: 278-82
67. Bolinger AM, So MH, Winter ME. Aminoglycoside and vancomycin pharmacokinetic monitoring in pediatric patients [letter]. Am J Hosp Pharm 1989; 46: 1770-1
68. Banner W, Ray CG. Vancomycin in perspective. Am J Dis Child 1984; 138: 14-6
69. Gous AGS, Dance MD, Lipman J, et al. Changes in vancomycin pharmacokinetics in critically ill infants. Anaesth Intensive Care 1995; 23: 678-82
70. Thompson CM, Long SS, Gilligan PH, et al. Absorption of oral vancomycin: possible associated toxicity. Int J Pediatr Nephrol 1983; 4: 1-4
71. Luer MS, Hatton J. Vancomycin administration into the cerebrospinal fluid: a review. Ann Pharmacother 1993; 27: 912-21
72. Fan-Havard P, Nahata MC, Bartowski MH, et al. Pharmacokinetics and cerebrospinal fluid (CSF) concentrations of vancomycin in pediatric patients undergoing CSF shunt placement. Chemotherapy 1990; 36: 103-8
73. McGee SNJ, Kaplan SL, Mason EO. Ventricular fluid concentrations of vancomycin in children after intravenous and intraventricular administration. Pediatr Infect Dis J 1990; 9: 138-9
74. Pau AK, Smego RA, Fisher MA. Intraventricular vancomycin: observations of tolerance and pharmacokinetics in two infants with ventricular shunt infections. Pediatr Infect Dis J 1986; 5: 93-6
75. Isaac DW, Pearson TA, Hurwitz CA, et al. Clinical and microbiologic aspects of Staphylococcus haemolyticus infections. Pediatr Infect Dis J 1993; 12: 1018-21
76. Klugman KP, Friedland IR, Bradley JS. Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrob Agents Chemother 1995; 39: 1988-92
77. Paris MM, Hickey SM, Uscher MI, et al. Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1994; 38: 1320-4
78. Cabellos C, Martinez-Lacasa J, Marios A, et al. Influence of dexamethasone on efficacy of ceftriaxone and vancomycin therapy in experimental pneumococcal meningitis. Antimicrob Agents Chemother 1995; 39: 2158-60
79. Bayston R, Hart CA, Barnicoat M. Intraventricular vancomycin in the treatment of ventriculitis associated with cerebrospinal fluid shunting and drainage. J Neurol Neurosurg Psychiatry 1987; 50: 1419-23
80. McLaurin RL, Frame PT. Treatment of infections with cerebrospinal fluid shunts. Rev Infect Dis 1987; 9: 595-603
81. Jacobs F, Delecluse F, Raftopoulos C, et al. Intraventricular vancomycin in CSF shunt infections. Neurosurgery 1987; 21: 112-3
82. Arroyo JC, Quindlen EA. Accumulation of vancomycin after intraventricular infusions. South Med J 1983; 76: 1554-5
83. Dagan O, Klein J, Gruenwald C, et al. Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit 1993; 15: 263-6
84. Spivey JM, Gal P. Vancomycin pharmacokinetics in neonates [letter]. Am J Dis Child 1986; 140: 859
85. Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm 1976; 4: 183-95
86. Murray WE. Vancomycin pharmacokinetics [letter]. Arch J Dis Child 1986; 140: 1096-7
87. Naqvi SH, Keenen W, Reichley R. Vancomycin pharmacokinetics in neonates [letter]. Am J Dis Child 1986; 140: 859
88. Baker D, Rotschafer JC, Sawchuk R, et al. Vancomycin pharmacokinetics [letter]. J Pediatr 1980; 97: 502-3
89. Gabriel MH, Gennrich JL. Vancomycin dosing for neonates [letter]. Pediatr Infect Dis J 1993; 12: 705-6